Moldova Citizenship-by-Investment Program Completes First Successful Application
As concessionaire of the Moldova Citizenship-by-Investment (MCBI) program, Henley & Partners is pleased to note the successful completion of the first citizenship-by-investment application in the country.
Henley & Partners has over 20 years of experience in strategic consulting, working with sovereign states around the globe in the design, set-up, and operation of the world’s most respected investment migration programs. The completion of the first citizenship-by-investment application process in Moldova clearly illustrates the features that are at the core of the MCBI program: impressive efficiency and a firm commitment to best practice. Within a three-month window, applicants are thoroughly screened in a multi-stage due diligence process that ensures only highly credible international investors are granted Moldovan citizenship.
There are currently over 30 applications in process, which is a testament to the international investment community’s growing appreciation of the value of the program and of Moldova as a prospective destination for foreign direct investment. As the most affordable citizenship-by-investment program on the European continent, the MCBI program offers investors significant value: successful applicants gain access to Europe’s Schengen Area and the post-Soviet region, a business-friendly environment, and a passport that facilitates travel access to 121 destinations around the world.
As well as the benefits it offers investors, the MCBI program will provide an ongoing income stream for Moldova that can be strategically and transparently invested in projects that enhance the lives of all citizens. It will build on an existing system that has successfully invested capital donated by the Millennium Challenge Corporation into infrastructure and agriculture. In the years ahead, the program is expected to act as a marketing platform for the country that will demonstrate the value of the Moldovan economy to prospective investors.
CEO of Henley & Partners Dr. Juerg Steffen commented: “This is an important first step for the MCBI program, and our decades of experience as the world’s leading investment migration firm makes us certain that further successes will soon follow. Among our industry’s many positive attributes, one of the most significant is its ability to provide nations with a considerable source of sustainable revenue without requiring them to become further indebted. The resulting increases in business activity and new employment opportunities lead to a more vibrant and positive socio-economic environment.”
Senior Group PR Manager
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Algomi ALFA Delivering Actionable Liquidity with Liquidnet and Trumid18.6.2019 15:06:00 EEST | Tiedote
Algomi, which provides data aggregation technology for the optimization of fixed income liquidity, today announced Algomi ALFA will enable orders to be executed on Liquidnet and Trumid. With this new functionality, Algomi ALFA goes beyond aggregating market data and liquidity to allow traders to efficiently navigate the markets and execute trades without duplicating steps across platforms. For actionable liquidity alerts, Algomi ALFA enables order staging and desktop interoperability. Algomi ALFA allows traders to engage with Liquidnet’s growing corporate bond liquidity on any actionable alert, by populating orders directly from ALFA before sending to Liquidnet via FIX. Liquidnet subsequently launches an active negotiation window to traders from its desktop application. Once the trade is completed, traders can view and export the execution report from ALFA. For Trumid, traders can engage with all Trumid actionable alerts from within Algomi ALFA, through Algomi’s graphical user interfac
AnyVision Closes $74 Million Series A with New Participation from M12 and DFJ Growth18.6.2019 14:10:00 EEST | Tiedote
AnyVision, a leading computer vision company specializing in face, body, and object-recognition software, today announced the close of its $74 million Series A financing round. New investment comes from M12, Microsoft’s venture fund, DFJ Growth and OG Technology Partners. As part of the Series A, AnyVision previously announced investment from LightSpeed Venture Partners, Robert Bosch GmbH, Qualcomm Ventures, and Eldridge Industries. AnyVision, founded in 2015, is a leading computer vision company specializing in face, body, and object-recognition software. AnyVision develops core software solutions that make all cameras smart. These solutions are agnostic to all cameras, computing frameworks, and use-cases. “There are very few times in business when you have the opportunity to build an entirely new industry alongside leading ecosystem players,” said Eylon Etshtein, CEO and Co-Founder of AnyVision. “We are fortunate to have the backing of chipmakers like Qualcomm, camera manufacturers s
IDEMIA Launches Augmented Vision, its Next Generation Video Analytics Application at IFSEC International18.6.2019 14:07:00 EEST | Tiedote
IDEMIA, the global leader in Augmented Identity, launches its video analytics application enhancing security in public and private places. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190618005513/en/ Credits: IDEMIA Augmented Vision supports security officers in identifying persons of interest in real-time, and helps speed up post-event investigations. This latest cutting-edge technology from IDEMIA will enhance security in transport hubs (airports, stations…), stadiums and arenas, retail and commercial buildings, as well as gaming and entertainment sites that face growing security challenges. The application is based on IDEMIA’s long-standing expertise in deep learning and biometrics for video and image analysis including IDEMIA’s facial recognition technology: a longstanding best-in-class combination of efficiency, scalability and accuracy for facial recognition as evidenced by IDEMIA’s leading position in the most rece
F-star Appoints Darlene Deptula-Hicks as Chief Financial Officer and Opens Office in Cambridge, MA18.6.2019 14:00:00 EEST | Tiedote
F-star Therapeutics Ltd., a clinical-stage biopharmaceutical company delivering tetravalent bispecific antibodies for a paradigm-shift in cancer therapy, today announces the appointment of Darlene Deptula-Hicks, MBA as Chief Financial Officer (CFO), succeeding Tolga Hassan, who is appointed to serve as F-star’s Chief Operating Officer. Darlene Deptula-Hicks joins F-star from Northern Biologics, Inc., a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody therapeutics in oncology. Previously, Darlene held CFO positions across both private and publicly listed US companies, including Pieris Pharmaceuticals Inc., Microline Surgical Inc. and T2 Biosystems Inc. She brings to F-star a proven track record of finance strategy and leadership, capital raising, industry knowledge and the ability to build strong strategic partnerships. Darlene Deptula-Hicks, CFO of F-star, said: “It is a very exciting time to be joining F-star given its evolution to a f
Norsk Titanium Receives Airbus Contract for Qualification and Production18.6.2019 13:00:00 EEST | Tiedote
Officials with Norsk Titanium (Norsk) announce today a contract award from Airbus for the Qualification and Serial Production of the first parts to be manufactured utilizing wire-based Direct Energy Deposition (DED) additive manufacturing technology. “We have worked closely with Airbus over several years to demonstrate the technological maturity and the industrial readiness of our Rapid Plasma Deposition™ (RPD™) process,” said Norsk President and CEO Michael Canario. “This contract award is structured to enable long-term, serial production immediately following qualification. Our Plattsburgh, New York facility, with the assistance of Airbus technical leadership, has been preparing for this moment and is eager to demonstrate a 21st century advanced additive manufacturing capability.” This qualification of Airbus parts will demonstrate the suitability of the DED additive manufacturing process for aircraft structural parts. It will formalize the process by which individual parts are produ
Axonics® Announces U.S. Food & Drug Administration Approves Use of Full-Body MRI for Pivotal Study Patients18.6.2019 13:00:00 EEST | Tiedote
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company focused on the development and commercialization of novel implantable sacral neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, today announced the U.S. Food & Drug Administration (“FDA”) approved the use of full-body magnetic resonance imaging (“MRI”) using 1.5 Tesla MRI scanners for clinical study patients implanted with the Axonics System. The approval was a result of a supplement filed by Axonics with the FDA under the Investigational Device Exemption (“IDE”) regarding the Company’s ARTISAN-SNM 129-patient pivotal clinical study. The FDA concluded that Axonics provided sufficient data to support full-body MRIs. Raymond W. Cohen, CEO of Axonics, commented, “Allowing full-body MRI scans for our clinical study patients means that none will have to undergo an explant of their neurostimulator device should they require an MRI. We view this as a very positive step by the FD
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme